Isocitrate dehydrogenase (IDH) mutations produce high levels of the 'oncometabolite' R-2-hydroxyglutarate (R-2-HG) and play a key role in the initiation and progression of glioma tumors in the brain. A recent study in Nature Cancer by Friedrich et al. describes how IDH-mutant-derived R-2-HG elicits an immunosuppressive phenotype in glioma-associated macrophages. As such, the authors uncovered a new vulnerability that can be exploited for therapy.
Keywords: R-2-hydroxyglutarate (R-2-HG); immunometabolism; immunosuppression; immunotherapy; isocitrate dehydrogenase (IDH)-mutant gliomas; tumor-associated macrophages.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.